Cargando…
Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer
Anaplastic thyroid cancer (ATC) comprises approximately 2% of all thyroid cancers, and its median survival rate remains poor because of its resistance to conventional therapy. Vascular endothelial growth factor receptor (VEGFR)-targeted therapeutics-loaded mesoporous silica nanoparticles represent a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419646/ https://www.ncbi.nlm.nih.gov/pubmed/30874973 http://dx.doi.org/10.1186/s11671-019-2924-z |
_version_ | 1783403986360991744 |
---|---|
author | Zhang, Ruiguo Zhang, Yueqian Tan, Jian Wang, Hanjie Zhang, Guizhi Li, Ning Meng, Zhaowei Zhang, Fuhai Chang, Jin Wang, Renfei |
author_facet | Zhang, Ruiguo Zhang, Yueqian Tan, Jian Wang, Hanjie Zhang, Guizhi Li, Ning Meng, Zhaowei Zhang, Fuhai Chang, Jin Wang, Renfei |
author_sort | Zhang, Ruiguo |
collection | PubMed |
description | Anaplastic thyroid cancer (ATC) comprises approximately 2% of all thyroid cancers, and its median survival rate remains poor because of its resistance to conventional therapy. Vascular endothelial growth factor receptor (VEGFR)-targeted therapeutics-loaded mesoporous silica nanoparticles represent a major advance for angiogenesis imaging and inhibition in lethal cancers. In the present study, we aimed to assess whether (131)I-labeled anti-VEGFR2 targeted mesoporous silica nanoparticles would have antitumor efficacy in an ATC tumor-bearing nude mouse model. Using in vitro and in vivo studies, we investigated the increased targeting ability and retention time in the anti-VEGFR2 targeted group using confocal microscopy and a γ counter. The tumor tissue radioactivity of the anti-VEGFR2 targeted group at 24 and 72 h after intratumoral injection was significantly higher than that of the non-targeted groups (all P < 0.05). Moreover, we found that radioactive accumulation was obvious even at 3 week post-injection in the anti-VEGFR2 targeted group via single-photon emission computed tomography/computed tomography, which was not seen at 3 day post-injection in the Na(131)I group. Meanwhile, compared with the non-targeted group, tumor growth in the targeted group was significantly inhibited, without causing apparent systemic toxic effects. Additionally, the median survival time in the targeted group (41 days) was significantly prolonged compared with that in the non-targeted (34 days) or Na(131)I (25 days) groups (both P < 0.01). Our data support the view that the as-developed (131)I-labeled anti-VEGFR2 targeted mesoporous silica nanoparticles showed promising results in ATC tumor-bearing mouse model and such an approach might represent a novel therapeutic option for ATC. |
format | Online Article Text |
id | pubmed-6419646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-64196462019-04-05 Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer Zhang, Ruiguo Zhang, Yueqian Tan, Jian Wang, Hanjie Zhang, Guizhi Li, Ning Meng, Zhaowei Zhang, Fuhai Chang, Jin Wang, Renfei Nanoscale Res Lett Nano Express Anaplastic thyroid cancer (ATC) comprises approximately 2% of all thyroid cancers, and its median survival rate remains poor because of its resistance to conventional therapy. Vascular endothelial growth factor receptor (VEGFR)-targeted therapeutics-loaded mesoporous silica nanoparticles represent a major advance for angiogenesis imaging and inhibition in lethal cancers. In the present study, we aimed to assess whether (131)I-labeled anti-VEGFR2 targeted mesoporous silica nanoparticles would have antitumor efficacy in an ATC tumor-bearing nude mouse model. Using in vitro and in vivo studies, we investigated the increased targeting ability and retention time in the anti-VEGFR2 targeted group using confocal microscopy and a γ counter. The tumor tissue radioactivity of the anti-VEGFR2 targeted group at 24 and 72 h after intratumoral injection was significantly higher than that of the non-targeted groups (all P < 0.05). Moreover, we found that radioactive accumulation was obvious even at 3 week post-injection in the anti-VEGFR2 targeted group via single-photon emission computed tomography/computed tomography, which was not seen at 3 day post-injection in the Na(131)I group. Meanwhile, compared with the non-targeted group, tumor growth in the targeted group was significantly inhibited, without causing apparent systemic toxic effects. Additionally, the median survival time in the targeted group (41 days) was significantly prolonged compared with that in the non-targeted (34 days) or Na(131)I (25 days) groups (both P < 0.01). Our data support the view that the as-developed (131)I-labeled anti-VEGFR2 targeted mesoporous silica nanoparticles showed promising results in ATC tumor-bearing mouse model and such an approach might represent a novel therapeutic option for ATC. Springer US 2019-03-14 /pmc/articles/PMC6419646/ /pubmed/30874973 http://dx.doi.org/10.1186/s11671-019-2924-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Nano Express Zhang, Ruiguo Zhang, Yueqian Tan, Jian Wang, Hanjie Zhang, Guizhi Li, Ning Meng, Zhaowei Zhang, Fuhai Chang, Jin Wang, Renfei Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer |
title | Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer |
title_full | Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer |
title_fullStr | Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer |
title_full_unstemmed | Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer |
title_short | Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer |
title_sort | antitumor effect of (131)i-labeled anti-vegfr2 targeted mesoporous silica nanoparticles in anaplastic thyroid cancer |
topic | Nano Express |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419646/ https://www.ncbi.nlm.nih.gov/pubmed/30874973 http://dx.doi.org/10.1186/s11671-019-2924-z |
work_keys_str_mv | AT zhangruiguo antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer AT zhangyueqian antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer AT tanjian antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer AT wanghanjie antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer AT zhangguizhi antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer AT lining antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer AT mengzhaowei antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer AT zhangfuhai antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer AT changjin antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer AT wangrenfei antitumoreffectof131ilabeledantivegfr2targetedmesoporoussilicananoparticlesinanaplasticthyroidcancer |